HNRNPA2B1 and thymic epithelial neoplasm: By drug repositioning and molecular dynamics simulations, a recent study pointed out that the compound ergotamine may become a reusable drug for treating recurrent thymic epithelial tumors (TET) by targeting hnRNPA2b1 [37].